参考文献/References:
[1]汪满满，杭于洁，刘千羽，等.氧化应激在肾纤维化中的作用机制及靶向治疗策略[J].中国医药导报,2025,22(13)：78-81.
[2]DE BOER I H,KHUNTI K,SADUSKY T,et al.Diabetes management in chronic kidney disease：A consensus report by the American Diabetes Association (ADA) and Kidney Disease：Improving Global Outcomes (KDIGO)[J].Diabetes Care,2022,45(12)：3075-3090.
[3]CHEN T K,KNICELY D H,GRAMS M E.Chronic kidney disease diagnosis and management：A review[J].JAMA,2019,322(13)：1294-1304.
[4]GUPTA A,NAGARAJU S P,BHOJARAJA M V,et al.Hypertension in chronic kidney disease：An Update on diagnosis and management[J].South Med J,2023,116(2)：237-244.
[5]WANG L,XU X,ZHANG M,et al.Prevalence of chronic kidney disease in china：Results from the sixth china chronic disease and risk factor surveillance[J].JAMA Intern Med,2023,183(4)：298-310.
[6]KIDNEY：IMPROVING GLOBAL OUTCOMES.2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int,2024,105(4S)：s117-s314.
[7]马飞，刘琳.肾衰宁片对单侧输尿管梗阻大鼠肾间质纤维化的改善作用及机制研究[J].陕西医学杂志,2022,51(6)：654-658.
[8]JOURDAN T,SZANDA G,ROSENBERG A Z,et al.Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy[J].Proc Natl Acad Sci U S A,2014,111(50)：e5420-e5428.
[9]PRESSLY J D,SONI H,JIANG S,et al.Activation of the cannabinoid receptor 2 increases renal perfusion[J].Physiol Genomics,2019,51(3)：90-96.
[10]张霞婧，井紫薇，朱芳芸，等.大麻素受体2激动剂在谷氨酸氧化应激损伤中保护作用实验研究[J].陕西医学杂志,2022,51(1)：25-28.
[11]ARCERI L,NGUYEN T K,GIBSON S,et al.Cannabinoid signaling in kidney disease[J].Cells,2023,12(10)：1419.
[12]VARGA Z V,MATYAS C,ERDELYI K,et al.Beta-caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice[J].Br J Pharmacol,2018,175(2)：320-334.
[13]OSAFO N,YEBOAH O K,ANTWI A O.Endocannabinoid system and its modulation of brain,gut,joint and skin inflammation[J].Mol Biol Rep,2021,48(4)：3665-3680.
[14]王蕾，杨涛，耿立成，等.内源性大麻素系统用于骨质疏松症预防与治疗的研究进展[J].天津医药,2023,51(9)：1020-1024.
[15]盛紫阳，栾仲秋，邓升华.苁蓉复肾方在抑制单侧输尿管梗阻大鼠肾间质纤维化中的应用及作用研究[J].陕西中医,2025,46(5)：594-599.
[16]SIMANKOWICZ P,STEPNIEWSKA J.The role of endocannabinoids in physiological processes and disease pathology：A comprehensive review[J].Journal of Clinical Medicine,2025,14(8)：2851.
[17]CAKIR M,TEKIN S,DOGANYIGIT Z,et al.Cannabinoid type 2 receptor agonist JWH-133,attenuates okadaic acid induced spatial memory impairment and neurodegeneration in rats[J].Life Sci,2019,217：25-33.
[18]ZOJA C,LOCATELLI M,CORNA D,et al.Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy[J].Nephron,2016,132(1)：59-69.
[19]练晨霞，胡思婧，张巧艳，等.植物大麻素2型受体调节剂抗炎作用研究进展[J].中国中药杂志,2023,48(23)：6294-6306.
[20]陈晨晨，宋珂，丁樱，等.雷公藤多苷对IgA肾病大鼠肾脏保护及肾组织CB2R/NOX4/NLRP3表达的影响[J].中国药理学通报,2024,40(11)：2037-2041.
[21]SHIN J I,LI H,PARK S,et al.induction and maintenance treatment of lupus nephritis：A Comprehensive review of meta-analyses[J].Journal of Clinical Medicine,2022,11(2)：343.
[22]MUKHOPADHYAY P,PAN H,RAJESH M,et al.CB1 cannabinoid receptors promote oxidative/nitrosative stress,inflammation and cell death in a murine nephropathy model[J].Br J Pharmacol,2010,160(3)：657-668.
[23]BARUTTA F,BELLINI S,MASTROCOLA R,et al.Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy[J].Br J Pharmacol,2018,175(23)：4371-4385.
[24]ACHARYA R,ZENG X,UPADHYAY K.Synthetic cannabinoid-associated acute interstitial nephritis：An emerging cause of pediatric acute kidney injury?[J].Clin Nephrol Case Stud,2023,11：55-60.
[25]LECRU L,DESTERKE C,GRASSIN-DELYLE S,et al.Cannabinoid receptor 1 is a major mediator of renal fibrosis[J].Kidney Int,2015,88(1)：72-84.
[26]BARUTTA F,PISCITELLI F,PINACH S,et al.Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy[J].Diabetes,2011,60(9)：2386-2396.
[27]HINDEN L,TAM J.Do endocannabinoids regulate glucose reabsorption in the kidney?[J].Nephron,2019,143(1)：24-27.
[28]EDDIN L B,MEERAN M,SUBRAMANYA S B,et al.Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis[J].Pharmacol Res Perspect,2024,12(6)：e1219.
[29]BARUTTA F,TRICARICO M,CORBELLI A,et al.Urinary exosomal microRNAs in incipient diabetic nephropathy[J].PLoS One,2013,8(11)：e73798.
[30]ZHOU L,ZHOU S,YANG P,et al.Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis[J].Kidney Int,2018,94(4)：756-772.
[31]NAM D H,LEE M H,KIM J E,et al.Blockade of cannabinoid receptor 1 improves insulin resistance,lipid metabolism,and diabetic nephropathy in db/db mice[J].Endocrinology,2012,153(3)：1387-1396.
[32]NAM D H,LEE M H,KIM J E,et al.Blockade of cannabinoid receptor 1 improves insulin resistance,lipid metabolism,and diabetic nephropathy in db/db mice[J].Endocrinology,2012,153(3)：1387-1396.
[33]TAM J,VEMURI V K,LIU J,et al.Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity[J].J Clin Invest,2010,120(8)：2953-2966.
[34]TROJNAR E,ERDELYI K,MATYAS C,et al.Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome[J].Free Radic Biol Med,2020,152：540-550.
[35]SUK K T,MEDERACKE I,GWAK G Y,et al.Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis[J].Gut,2016,65(10)：1721-1732.
[36]ZHOU S,LING X,LIANG Y,et al.Cannabinoid receptor 2 plays a key role in renal fibrosis through inhibiting lipid metabolism in renal tubular cells[J].Metabolism,2024,159：155978.
[37]DHOPESHWARKAR A,MACKIE K.CB2 Cannabinoid receptors as a therapeutic target：What does the future hold?[J].Mol Pharmacol,2014,86(4)：430-437.
[38]CHUA J T,ARGUETA D A,DIPATRIZIO N V,et al.Endocannabinoid system and the kidneys：From renal physiology to injury and disease[J].Cannabis Cannabinoid Res,2019,4(1)：10-20.